Depressive symptoms that emerge during intoxication, withdrawal, or chronic exposure to a psychoactive substance or prescribed medication are common, often missed, and frequently mistaken for a primary mood disorder. Substance/medication-induced depressive disorder sits in the DSM-5-TR Depressive Disorders chapter and requires a temporal link between the agent and the mood disturbance, symptoms severe enough to warrant clinical attention, and a presentation that is not better explained by an independent depressive illness. The distinction matters because the right intervention is often removal of the offending agent rather than reflexive initiation of an antidepressant. Alcohol, sedative-hypnotics, opioids, stimulants in withdrawal, interferon-alfa, glucocorticoids, and several antihypertensives are the highest-yield culprits to recognize on the wards and in clinic. Diagnostic confidence usually grows with observation across an abstinence or washout window, calibrated to the pharmacokinetics of the agent. Bottom line: before adding a drug, ask what drug might be causing the depression.

Substance- and medication-induced depressive presentations are common in clinical settings but underdiagnosed because clinicians rarely re-examine the differential after a depressive episode is named. Prevalence varies sharply by exposure and treatment setting.

Population estimates

• Substance-induced mood disorders account for a meaningful minority of new-onset depressive presentations in addiction treatment settings, with alcohol the most frequent driver. ^1-2
• In the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), a small but clinically important share of lifetime major depressive episodes met criteria for substance-induced rather than independent depression. ³
• Among patients receiving interferon-alfa for chronic hepatitis C, depressive symptoms developed in roughly a third over the treatment course, and a smaller subset met criteria for a full depressive syndrome. ⁴
• High-dose systemic glucocorticoids are associated with mood symptoms in a substantial minority of recipients, with depressive features more common at lower doses and during taper, and manic or mixed features more common at higher doses. ⁵

Age and sex

• Onset tracks the age distribution of the inciting exposure rather than the bimodal age curve of primary major depressive disorder. ¹
• Female sex, prior depressive episodes, and family history of mood disorder increase risk across most pharmacologic triggers. ^4-5

High-yield risk factors

• Higher doses, longer exposure, and rapid dose changes (initiation or withdrawal) raise risk. ^5-6
• Polypharmacy and concurrent alcohol use compound risk in older adults. ⁶
• Comorbid medical illness with its own depressive risk (HCV, malignancy, Cushing syndrome) magnifies attributable risk. ^4-5

Mechanisms differ by agent but converge on a small number of pathways: monoaminergic depletion or downregulation, neuroinflammation, HPA-axis dysregulation, and disruption of reward circuitry. Knowing the mechanism predicts the time course and informs treatment choice.

Neurotransmitter and circuit effects

• Chronic alcohol use reduces serotonergic tone and produces downstream changes in glutamatergic and GABAergic signaling that persist into early abstinence. ⁷
• Stimulant withdrawal produces transient hypodopaminergia in mesolimbic and mesocortical circuits, manifesting as anhedonia, fatigue, and dysphoria. ⁸
• Chronic opioid exposure dysregulates the locus coeruleus and reward circuitry, with extended dysphoria after acute withdrawal resolves. ⁹

Inflammation and HPA axis

• Interferon-alfa induces depressive symptoms through cytokine-mediated reductions in tryptophan availability, kynurenine pathway activation, and serotonergic dysfunction. ^4,10
• Glucocorticoids alter hippocampal function, BDNF expression, and HPA-axis feedback, with rapid mood changes at high doses. ⁵

Genetic and trait vulnerability

• Family history of mood disorder and prior depressive episodes increase incident depression on interferon-alfa, glucocorticoids, and during stimulant or alcohol withdrawal. ^4-5,7
• Polymorphisms in serotonergic and inflammatory genes have been associated with interferon-induced depression, though clinical utility remains limited. ¹⁰

Integrative model

• Substance- and medication-induced depression is best understood as a perturbation of mood-regulating circuitry by an exogenous agent in a vulnerable host, with the duration of symptoms tracking the pharmacokinetics of the offending exposure and the resilience of the underlying system. ^1,7

DSM-5-TR places this condition within the depressive disorders. The defining feature is a persistent disturbance in mood, with depressed mood or markedly diminished interest or pleasure, that arises in temporal association with a substance, medication, or toxin known to produce such effects.

Core DSM-5-TR criteria

• A prominent and persistent disturbance in mood characterized by depressed mood or markedly diminished interest or pleasure in most activities. ¹¹
• Evidence from history, examination, or laboratory findings that the symptoms developed during or soon after substance intoxication, withdrawal, or exposure to a medication capable of producing the symptoms. ¹¹
• The disturbance is not better explained by an independent depressive disorder, evidenced by symptoms preceding onset of substance use, persistence beyond the expected washout period (often noted as roughly one month, with clinical judgment), or other supporting history. ¹¹
• Symptoms do not occur exclusively during a delirium and cause clinically significant distress or impairment in functioning. ¹¹

Specifiers

• Onset during intoxication. ¹¹
• Onset during withdrawal. ¹¹
• Onset after medication use. ¹¹
• The specific substance is named in the diagnosis (for example, alcohol-induced depressive disorder, with onset during withdrawal). ¹¹

ICD-11 differences

• ICD-11 codes substance-induced mood disorders within the substance-use chapter rather than the mood-disorders chapter and uses slightly different temporal qualifiers, but the clinical construct is closely aligned with DSM-5-TR. ¹²

The clinical picture often resembles a primary depressive episode but is shaped by the pharmacology of the offending agent and the timing of exposure or withdrawal. Recognition rests on a careful timeline.

Common symptom clusters

• Depressed mood, anhedonia, fatigue, sleep disturbance, appetite change, and impaired concentration. ¹¹
• Psychomotor retardation is common in withdrawal-related presentations from sedatives, opioids, and stimulants. ^8-9
• Suicidal ideation can be prominent, particularly during stimulant or alcohol withdrawal and during interferon-alfa treatment. ^4,8

Agent-specific patterns

• Alcohol: depressive symptoms peak in the first one to four weeks of abstinence and typically remit substantially by week three to four in most patients. ^2,7
• Stimulants (cocaine, methamphetamine): acute crash with hypersomnia, hyperphagia, and dysphoria over days, with anhedonia and fatigue that can persist for weeks. ⁸
• Opioids: low mood and anhedonia accompany the protracted abstinence syndrome and may persist for months. ⁹
• Interferon-alfa: gradual onset over weeks of treatment, often with neurovegetative features prominent early and cognitive and affective features later. ^4,10
• Glucocorticoids: depressive features more common with prolonged use or during taper; hypomanic and mixed features more common acutely at high doses. ⁵
• Antihypertensives (notably beta-blockers and centrally acting agents): older literature linked reserpine and methyldopa to depression; the depressive risk from contemporary beta-blockers appears small and inconsistent. ¹³

Red flags suggesting an independent disorder

• Depressive episodes preceding first substance exposure or first medication course. ¹¹
• Persistence well beyond the agent's pharmacokinetic washout. ¹¹
• Depressive episodes during sustained abstinence in the past. ^1,11

The central diagnostic question is whether the depressive syndrome is caused by, comorbid with, or independent of the substance or medication. The differential extends beyond mood disorders to medical mimics that share symptoms with depression.

Primary depressive disorders

• Major depressive disorder with comorbid substance use is the most important alternative; the timeline and behavior of symptoms during abstinence are the most useful discriminators. ^1,11
• Persistent depressive disorder presents with chronic low-grade symptoms typically predating the substance exposure. ¹¹
• Bipolar depression should be considered when there is a history of manic or hypomanic episodes; stimulants and steroids can also unmask underlying bipolar diathesis. ^5,11

Other psychiatric conditions

• Adjustment disorder with depressed mood when symptoms are tied to a stressor rather than an agent. ¹¹
• Demoralization in the context of chronic illness, particularly in patients on multiple medications. ¹⁴

Medical mimics to rule out

• Hypothyroidism, hyperthyroidism, and other endocrinopathies including Cushing syndrome and Addison disease. ¹⁴
• B12 and folate deficiency, particularly in alcohol use disorder and older adults. ¹⁴
• Anemia, electrolyte derangement, and uremia. ¹⁴
• Neurologic disorders including stroke, Parkinson disease, multiple sclerosis, and traumatic brain injury. ¹⁴
• Occult malignancy, including pancreatic cancer in patients with new-onset depression and weight loss. ¹⁴

High-yield offending agents

Assessment hinges on a tight clinical timeline that aligns mood symptoms with exposure, intoxication, withdrawal, and abstinence. Standardized scales help measure severity but do not establish attribution.

History elements that must be obtained:

• Full chronology of substance use and prescribed medications, including doses, start and stop dates, recent changes, and concurrent over-the-counter and complementary agents. ^11,14
• Sequence of mood symptoms relative to each exposure and to any prior abstinence periods. ¹¹
• Personal and family history of mood, anxiety, and psychotic disorders, with particular attention to any manic or hypomanic episodes. ¹¹
• Suicide risk assessment, including ideation, plan, intent, prior attempts, and access to lethal means. ¹⁵

Physical examination

• Look for signs of intoxication or withdrawal (autonomic changes, tremor, miosis or mydriasis, agitation). ¹⁴
• Identify stigmata of chronic substance use (hepatomegaly, spider angiomata, track marks). ¹⁴
• Screen for stigmata of endocrinopathy (goiter, moon facies, striae, hypothyroid skin and reflexes). ¹⁴

Validated rating scales

• PHQ-9 for depressive symptom severity and longitudinal tracking. ¹⁶
• HAM-D in research and specialty settings. ¹⁴
• AUDIT and DAST for substance use screening when not already obtained. ¹⁷
• Columbia Suicide Severity Rating Scale (C-SSRS) for structured suicide risk assessment. ¹⁵

Laboratory and imaging work-up

• Basic labs to exclude common mimics: CBC, comprehensive metabolic panel, TSH, B12, folate, and urinalysis. ¹⁴
• Urine drug screen and blood alcohol level when relevant. ¹⁴
• Targeted endocrine testing (cortisol, dexamethasone suppression, HCG in females) when clinical features suggest. ¹⁴
• Neuroimaging only when neurologic signs, atypical presentation, or first late-onset episode raises concern. ¹⁴

What not to order

• Routine neuroimaging in uncomplicated cases lacks yield. ¹⁴
• Broad genetic or pharmacogenomic panels are not indicated at the initial diagnostic stage. ²⁰

The cornerstone is identification and, where feasible, removal or substitution of the offending agent, paired with safe management of any associated withdrawal syndrome. Antidepressants have a smaller and more specific role than in primary depression.

Pharmacotherapy

• Remove or substitute the offending medication when clinically possible, balancing the indication against the depressive risk. ^1,5
• For interferon-alfa-induced depression, evidence suggests SSRIs (commonly paroxetine or citalopram in trials) reduce incidence and severity, and prophylactic treatment in high-risk patients is supported by limited evidence. ^4,18
• For corticosteroid-induced mood symptoms, lower the dose where feasible; evidence suggests lithium prophylaxis can reduce risk in high-risk regimens, and atypical antipsychotics or mood stabilizers are used for manic or mixed presentations. ⁵
• For alcohol-related depressive symptoms, an observation window of two to four weeks of abstinence is commonly recommended before initiating an antidepressant, since most symptoms remit. ^2,7
• For persistent depressive symptoms after a reasonable abstinence window, SSRIs are commonly recommended, with evidence strongest for sertraline in patients with comorbid alcohol use disorder. ¹⁹
• For stimulant withdrawal, supportive care and time are the foundation; antidepressants have not shown consistent benefit, and bupropion has been studied for stimulant use disorder rather than depression per se. ⁸
• For opioid-related depression, evidence suggests medications for opioid use disorder (methadone, buprenorphine) improve mood as part of their core effect; antidepressants are used when depression persists. ⁹

Psychotherapy

• Cognitive behavioral therapy for substance use and depression has strong evidence and is commonly recommended as an adjunct or alternative to medication. ²⁰
• Motivational interviewing is recommended to support engagement with abstinence or dose reduction. ²⁰
• Behavioral activation is useful when anhedonia and inactivity dominate. ²⁰

Neuromodulation

• Reserved for severe, persistent depression after the offending agent is removed and primary depression is established; electroconvulsive therapy follows the same indications as in primary major depressive disorder. ²¹

Adjunctive

• Treat comorbid medical contributors (thyroid, B12, sleep apnea). ¹⁴
• Address sleep with non-pharmacologic measures first; avoid long-term benzodiazepines and Z-drugs in this population given dependence and depressive risk. ²²
• Coordinate with primary teams when the offending agent has an essential indication (oncology, transplant, autoimmune disease). ^4-5

Harms accrue from two directions: from the offending agent itself, and from over-treatment of mood symptoms that would have remitted with abstinence or dose reduction. The evidence base is also uneven across agents.

Common harms picture

• Antidepressant adverse effects when given unnecessarily during a transient withdrawal-related depressive state. ²²
• Continued exposure to the offending agent when its indication is non-essential or substitutable. ^1,5
• Premature labeling of a patient with a primary depressive disorder, anchoring future treatment. ¹¹

Serious or rare harms

• Suicide during early abstinence from alcohol or stimulants, even when overall depressive symptoms are improving. ^8,15
• Serotonin syndrome when SSRIs are combined with serotonergic agents (linezolid, MAOIs, some opioids). ²²
• Lithium toxicity when used prophylactically in steroid mood prevention, particularly with concurrent diuretics or NSAIDs. ²³

Monitoring and discontinuation

• Re-evaluate the diagnosis at the end of the agent-specific washout window and at four to six weeks of abstinence. ¹¹
• Reassess antidepressant need rather than continuing indefinitely when the trigger was clearly substance- or medication-induced. ^1,11
• Taper SSRIs and SNRIs to limit discontinuation syndrome. ²²

Limitations of the evidence

• Most data come from observational cohorts and treatment-context-specific trials (interferon, steroids, alcohol) rather than head-to-head RCTs in substance-induced depression broadly. ^4-5,19
• Diagnostic attribution is operator-dependent and influenced by access to a reliable substance use history. ^1,11
• Publication bias and small sample sizes limit confidence in many subgroup findings. ^4-5

Risk and management differ by life stage, comorbidity, and treatment context.

Pediatric

• Adolescents are exposed to alcohol, cannabis, stimulants, and prescribed medications (isotretinoin, levetiracetam, contraceptives); maintain a low threshold for considering substance- or medication-induced presentations. ¹¹
• Population-level data have not shown a consistent increased depression risk from isotretinoin, though individual cases support vigilance. ²⁴

Geriatric

• Polypharmacy is a major driver of medication-induced depression; common contributors include opioids, benzodiazepines, anticholinergics, antiparkinsonian agents, and some antihypertensives. ^6,14
• Beers Criteria highlight medications associated with mood and cognitive risks in older adults. ²⁵

Perinatal

• Hormonal transitions and treatment exposures (GnRH analogs, oral contraceptives, progestin-only methods) can produce mood symptoms in susceptible patients. ²⁶
• Distinguish substance- or medication-induced depression from perinatal depression, and consider lactation-compatible options when treatment is indicated. ²⁶

Comorbid medical illness

• Oncology patients on interferon, interleukins, and steroid-containing regimens carry substantial mood risk; collaborative care models improve outcomes. ^4,27
• Transplant recipients on chronic glucocorticoids and calcineurin inhibitors require coordinated psychiatric and transplant care. ^5,27

Comorbid substance use

• In patients with active substance use, abstinence-based observation is the most useful diagnostic tool; do not defer treatment if symptoms are severe or include active suicidality. ^1,15
• Integrated care for substance use disorder and depression improves outcomes over sequential or parallel care. ²⁷

Cultural considerations

• Symptom expression and substance use patterns vary across populations; obtain a culturally informed history and account for stigma in disclosure of use. ¹¹

Outcomes depend on whether the offending agent can be removed and whether an independent depressive disorder is also present.

Natural history

• Most substance-induced depressive presentations remit within weeks of abstinence and dose adjustment, with alcohol-related symptoms typically improving substantially over 3-4 weeks. ^2,7
• Persistence beyond 4 weeks of abstinence raises the likelihood of an independent depressive disorder. ¹¹
• Interferon-induced depression usually resolves within weeks of treatment completion in most patients. ⁴

Response and recurrence

• Response to SSRIs in interferon-induced depression mirrors response patterns in primary depression. ^4,18
• Recurrence is high if the offending agent is reintroduced; document the prior reaction prominently in the chart. ^1,5

Suicide risk

• Suicidal ideation and behavior are elevated during alcohol and stimulant withdrawal and during interferon-alfa treatment. ^4,8,15
• Long-term suicide risk in patients with substance use disorders and recurrent depressive episodes is elevated relative to the general population. ¹⁵

Functional outcomes

• Functional recovery tracks resolution of the mood episode and the underlying substance use disorder; persistence of either predicts ongoing impairment. ¹

Acute presentations are common, particularly in emergency departments and consultation services. Decisions hinge on safety and on identifying treatable contributors.

Hospitalization criteria

• Active suicidal ideation with plan or intent, recent attempt, or inability to maintain safety in the community. ¹⁵
• Severe withdrawal syndromes (alcohol, sedative-hypnotic) requiring medically supervised management. ²²
• Severe depression with psychotic features, catatonia, or marked self-neglect. ¹¹

Suicide risk markers

• Recent loss, escalating substance use, access to firearms, and prior attempts elevate near-term risk. ¹⁵
• Acute intoxication impairs judgment and increases impulsivity; defer definitive disposition until the patient is clinically sober when safe to do so. ¹⁵

Agitation management

• Verbal de-escalation and environmental control first; use targeted pharmacologic agents when needed, with attention to the offending substance (avoid benzodiazepines in opioid-intoxicated patients unless treating concurrent benzodiazepine or alcohol withdrawal). ²⁸

Safety-relevant comorbidities

• Co-occurring traumatic brain injury, alcohol withdrawal, and infection (delirium tremens, encephalopathy, sepsis) can mimic or magnify a depressive presentation; identify and treat first. ^14,22

Several long-running debates shape day-to-day diagnostic and prescribing practice.

Diagnostic threshold and washout window

• The DSM-5-TR note that symptoms persisting beyond about one month off the agent suggest an independent disorder is a clinical guide rather than a strict cutoff; the optimal washout varies by agent and individual. ¹¹
• Operationalizing attribution in research is difficult and may underestimate or overestimate the construct depending on instrument and setting. ¹

Antidepressants in early abstinence

• Whether to initiate antidepressants during the first weeks of alcohol abstinence remains debated; many guidelines recommend observation, others support earlier initiation in severe presentations. ^2,7,19

Beta-blockers and depression

• Older case reports and small studies suggested a link between propranolol and depression, but contemporary cohort and meta-analytic data do not show a consistent increased risk; reflexive avoidance is no longer warranted. ¹³

Isotretinoin and depression

• The relationship between isotretinoin and depression has been studied extensively; population-level data do not show a consistent increase in depression risk, but post-marketing reports and patient-level concerns persist. ²⁴

Hormonal contraceptives

• Some large registry studies have suggested a small association between hormonal contraceptive use and incident depression, particularly in adolescents; clinical guidance does not contraindicate use but supports counseling and monitoring. ²⁶

Cannabis and depression

• Cannabis is associated with depressive symptoms, particularly with heavy use beginning in adolescence, but causal attribution at the individual level remains uncertain. ²⁹

• DSM-5-TR places substance/medication-induced depressive disorder within the depressive disorders chapter and requires a temporal link between the agent and mood symptoms. ¹¹
• Symptoms persisting beyond about one month after cessation of the offending agent suggest an independent depressive disorder. ¹¹
• Alcohol-related depressive symptoms typically remit substantially within 3-4 weeks of abstinence. ^2,7
• Stimulant withdrawal causes a crash characterized by hypersomnia, hyperphagia, and dysphoria, followed by prolonged anhedonia. ⁸
• Interferon-alfa induces depression in roughly a third of treated patients, with SSRI prophylaxis or treatment supported by RCT evidence. ^4,18
• Glucocorticoid-induced mood symptoms are dose- and duration-dependent; depressive features predominate with lower doses and tapering, mixed and manic features with higher doses. ⁵
• Lithium prophylaxis can reduce the risk of corticosteroid-induced mood symptoms in high-risk regimens. ⁵
• Reserpine and methyldopa are the classic antihypertensive culprits historically linked to depression; contemporary beta-blocker risk appears small and inconsistent. ¹³
• Sertraline has the strongest SSRI evidence for depression with comorbid alcohol use disorder. ¹⁹
• Medications for opioid use disorder (methadone, buprenorphine) improve mood as part of treating the core disorder. ⁹
• Suicide risk is elevated during alcohol and stimulant withdrawal even as overall mood symptoms appear to improve. ^8,15
• Polypharmacy is a leading cause of medication-induced depression in older adults; Beers Criteria flag many of the offending agents. ^6,25
• Routine neuroimaging is not indicated in uncomplicated substance- or medication-induced depression. ¹⁴
• ICD-11 codes substance-induced mood disorders within the substance-use chapter, in contrast to DSM-5-TR's placement in mood disorders. ¹²
• ECT remains indicated for severe, persistent depression after the offending agent is removed and primary depression is established. ²¹

No external funding. No conflicts of interest declared. Peer-review status: pending.